Browsing Category
Pharma Industry News
4724 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Why NervGen Pharma Corp’s Chief Financial Officer retirement matters more than it appears
NervGen Pharma Corp announces its Chief Financial Officer’s planned retirement. Find out what the leadership change signals for capital strategy and investors.
Why Vistagen Therapeutics Inc.’s PALISADE-4 trial may matter more than its cash runway
Find out how Vistagen Therapeutics Inc. is advancing PALISADE-4 with $61.8M in cash and tackling placebo risk in CNS trials. Read the analysis.
Why MetaVia’s patent move may matter more than early weight loss data in the obesity market
MetaVia Inc. secures patent protection for its dual incretin obesity drug DA-1726 through 2041. Find out why this matters for investors and competitors.
Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms
Natural Capsules Limited’s Q3 FY26 results reveal regulatory recovery, tariff relief, and lingering API risks. Find out what this means for investors next.
Why Eli Lilly and Company is stockpiling a weight loss pill before the FDA has even said yes
Eli Lilly and Company is ramping inventory ahead of a key FDA decision on its oral weight loss pill. Find out what this signals for obesity drugs and investors.
Longeveron Inc. appoints Stephen H. Willard as CEO ahead of pivotal Phase 2b stem cell data
Find out why Longeveron Inc.’s CEO appointment comes at a critical clinical and financial moment and what it could mean for investors and regenerative medicine.
Philadelphia jury orders Johnson & Johnson to pay $250,000 in talc powder lawsuit
Johnson & Johnson faces a new talc verdict in Philadelphia. Find out why even a small award still matters for investors and long-term strategy.
FDA Complete Response Letter puts Disc Medicine Inc.’s bitopertin timeline under pressure
Disc Medicine Inc. shares plunge after the FDA issues a Complete Response Letter for bitopertin. Find out what this setback means for investors and strategy.
What new Dupilumab data suggest about long-term immune control in allergic disease at Regeneron Pharmaceuticals
New Dupilumab analyses highlight immune modulation claims. Read how Regeneron Pharmaceuticals is testing durability, reimbursement logic, and long-term strategy.
NATCO Pharma (NSE: NATCOPHARM) wins CDSCO approval for semaglutide as FDA compliance risks recede at its API unit
NATCO Pharma Limited secures CDSCO approval for semaglutide as U.S. FDA risks ease. Find out what this means for growth, execution, and investors.